Nicotinamide ( DrugBank: Nicotinamide )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病4
49全身性エリテマトーデス1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05589766
(ClinicalTrials.gov)
November 28, 202213/10/2022N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's DiseaseN-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's DiseaseParkinson DiseaseDietary Supplement: Nicotinamide Riboside;Other: PlaceboHaukeland University HospitalNULLRecruiting40 Months100 YearsAll80N/ANorway
2NCT03568968
(ClinicalTrials.gov)
May 15, 202014/6/2018A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's DiseaseA Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK StudyParkinson DiseaseDietary Supplement: Nicotinamide Riboside;Drug: PlaceboHaukeland University HospitalNULLRecruiting18 YearsN/AAll400N/ANorway
3NCT03816020
(ClinicalTrials.gov)
March 9, 20197/12/2018NAD-supplementation in Drug naïve Parkinson's DiseaseNAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's DiseaseParkinson Disease;Neurodegenerative DiseasesDietary Supplement: Nicotinamide Riboside;Other: PlaceboHaukeland University HospitalNULLCompleted18 YearsN/AAll30N/ANorway
4EUCTR2004-005034-39-GB
(EUCTR)
17/05/200520/04/2005Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's diseaseNicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease Idiopathic Parkinson's diseaseTrade Name: Nicotinamide
Product Name: NICOTINAMIDE
INN or Proposed INN: Nicotinamide
Queen Elizabeth HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
United Kingdom

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03260166
(ClinicalTrials.gov)
August 31, 201710/8/2017Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus ErythematosusAn Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus ErythematosusCutaneous Lupus Erythematosus;Systemic Lupus Erythematosus RashDrug: nicotinamideSecond Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China;Hunan Provincial Natural Science Foundation of China;National Key Clinical Specialty Construction Project of ChinaActive, not recruiting18 Years65 YearsAll40Phase 2China